Rodrigo Dienstmann
← Back to Universitat de Vic - Universitat Central de Catalunya
Universitat de Vic - Universitat Central de Catalunya
Rodrigo Dienstmann works in Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Genetic factors in colorectal cancer. Recorded institutional associations include Universitat de Vic - Universitat Central de Catalunya, Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari.
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
The consensus molecular subtypes of colorectal cancer
2015 · 5,142 citationsRecommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
2020 · 1,186 citationsConsensus molecular subtypes and the evolution of precision medicine in colorectal cancer
2017 · 1,021 citationsA framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
2018 · 815 citationsDevelopment of PI3K inhibitors: lessons learned from early clinical trials
2013 · 766 citationsCIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer
2017 · 624 citationsCancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
2018 · 519 citationsPicking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 · 462 citationsRecommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
2024 · 415 citationsPhase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
2015 · 388 citationsGenomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
2013 · 365 citationsA Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations
2018 · 359 citationsTargeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
2010 · 355 citationsPersonalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients
2015 · 343 citationsMolecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes
2014 · 330 citationsA RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
2018 · 268 citationsColorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
2017 · 255 citationsPrediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study
2017 · 237 citationsESMO Guidance for Reporting Oncology real-World evidence (GROW)
2023 · 234 citationsRelative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer
2019 · 228 citationsMinimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis
2020 · 191 citationsConcordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
2017 · 187 citationsErratum: Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
2017 · 183 citationsTankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer
2015 · 178 citationsPhase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
2014 · 173 citations
